Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
23andMe to Cut 40% of Its Staff
23andMe cuts 40% of its workforce and discontinues therapeutics division
Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.
23andMe to Cut 40% of Its Staff Amid Grim Financials
The DNA testing kit company is also discontinuing new developments to its therapeutics program, which has been focused on using customers’ DNA data to aid in drug discovery.
23andMe cuts 40% of its workforce
Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to "streamline operations and reduce costs."
1d
on MSN
23andMe customer? Here's what to know about the privacy of your genetic data.
Concerns about 23andMe's business prospects is raising questions about the genetic testing company's customer data.
2d
on MSN
After its entire board resigned overnight, 23andMe will cut over 200 employees and its cancer research in an urgent bid to nurse the company back to health
The DNA-testing firm said in a Tuesday SEC filing, “there is substantial doubt about the company’s ability to continue.” ...
medtechdive
1d
23andMe to lay off more than 200 employees amid business struggles
The genetic testing firm will also close its therapeutics arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the ...
FierceBiotech
3d
23andMe shutters cancer drug research programs, lays off 40% of staff
investigators and study staff for their participation in our clinical trials,” co-founder and CEO
Anne
Wojcicki
said in a ...
Benzinga.com
2d
Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs
“We are taking these difficult but necessary actions as we restructure
23andMe
and focus on the long-term success of our ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback